Inovio Biomedical’s First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu In Pre-Clinical Testing
Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced recently pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company’s proprietary electroporation delivery technology and, specifically, a new intradermal device.
